The Company is a biotechnology business that is located in Southern California. The Company’s senior management and principal partners are Minh Nguyen and Chinh Vu. Together, these senior executives have more than 50 years of collective experience in the biotechnology and pharmaceutical industries.
The Company is seeking to raise private funding of at least USD20 million to build a manufacturing facility to manufacture molecular diagnostic products to fulfill orders for its H-project: HPV, HIV, HBV, and HCV. These real-time q-PCR assays are required in developing markets such as Asia-Pacific and Sahara-Africa.
Concurrently, the Company plans to develop and produce its first five Point of Care (POC) proteomic diagnostic products:
— TSH assay,
— Testosterone assay,
— PSA assay,
— Free T4 (FT4),
— Free T3 (FT3).
These proteomic assays meet unfullfilled needs within the global POC market. The Company plans to leverage its proprietary technical knowledge, current/existing diagnostic platform technology, and deep global networks to push at least 27 molecular/proteomic assays to selected global markets including South-East Asia, Africa, and Americas.
As insurance for Return of Investment (ROI), Gnosis will use its initial profit to invest into independent clinical labs, which will instantly generate the cash flow to support its product development; and to ready Gnosis for its 5-year plan: having facets to detect and treat diseases and medical conditions, including various types of cancers and viral infections.